Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$338.91 - $506.01 $508,365 - $759,015
1,500 New
1,500 $570,000
Q2 2022

Aug 15, 2022

SELL
$269.58 - $378.88 $1.32 Million - $1.86 Million
-4,898 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$254.45 - $351.06 $1.25 Million - $1.72 Million
4,898 New
4,898 $1.54 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.